Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
McKesson
Mallinckrodt
Harvard Business School
Baxter

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Celgene Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Celgene

Drugs and US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 RX Yes Yes 8,315,886   See Pricing   See Pricing
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 RX Yes No 9,872,854   See Pricing   See Pricing
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-002 Jan 17, 2003 RX Yes No 7,959,566   See Pricing   See Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 RX Yes No 8,404,717   See Pricing   See Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 RX Yes Yes 7,189,740   See Pricing   See Pricing
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-002 Feb 8, 2013 RX Yes No 8,828,427   See Pricing Y Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 8,204,763   See Pricing
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 8,288,415   See Pricing
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-004 Feb 8, 2013 8,204,763   See Pricing
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 7,435,745   See Pricing
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 6,561,976   See Pricing
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 6,561,976   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CELGENE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 1 mg, 2 mg, 3 mg and 4 mg ➤ Subscribe 2017-02-08
➤ Subscribe Capsules 5 mg, 10 mg and 15 mg ➤ Subscribe 2010-08-30
➤ Subscribe Capsules 50 mg and 100 mg ➤ Subscribe 2006-12-18
➤ Subscribe Capsules 150 mg ➤ Subscribe 2014-02-03
➤ Subscribe Tablets 10 mg, 20 mg and30 mg ➤ Subscribe 2018-03-22
➤ Subscribe Capsules 25 mg ➤ Subscribe 2010-07-12
➤ Subscribe Capsules 2.5 mg and 20 mg ➤ Subscribe 2016-07-12
➤ Subscribe Capsules 200 mg ➤ Subscribe 2006-09-25
➤ Subscribe Injection 10 mg/vial ➤ Subscribe 2013-11-05

Supplementary Protection Certificates for Celgene Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0925294 07C0056 France   See Pricing PRODUCT NAME: LENALIDOMIDE; REGISTRATION NO/DATE: EU/1/07/391/001-004 20070618
0688211 SPC/GB08/039 United Kingdom   See Pricing PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416
0688211 08C0036 France   See Pricing PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
2105135 122015000013 Germany   See Pricing PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
0925294 56/2007 Austria   See Pricing PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES; REGISTRATION NO/DATE: EU/1/07/391/001 - EU/1/07/391/004 20070614
2105135 C300717 Netherlands   See Pricing PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Boehringer Ingelheim
Medtronic
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.